CN117356711A - Synbiotic with function of improving bile acid metabolism and application thereof - Google Patents

Synbiotic with function of improving bile acid metabolism and application thereof Download PDF

Info

Publication number
CN117356711A
CN117356711A CN202210771360.6A CN202210771360A CN117356711A CN 117356711 A CN117356711 A CN 117356711A CN 202210771360 A CN202210771360 A CN 202210771360A CN 117356711 A CN117356711 A CN 117356711A
Authority
CN
China
Prior art keywords
product
gup
oligosaccharide
prebiotics
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210771360.6A
Other languages
Chinese (zh)
Inventor
王辰元
孙二娜
孟昭旭
李树森
牛天娇
康小红
刘巨龙
肖然
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Mengniu Dairy Group Co Ltd
Original Assignee
Inner Mongolia Mengniu Dairy Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Mengniu Dairy Group Co Ltd filed Critical Inner Mongolia Mengniu Dairy Group Co Ltd
Priority to CN202210771360.6A priority Critical patent/CN117356711A/en
Publication of CN117356711A publication Critical patent/CN117356711A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/34—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds characterised by carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G9/363—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/38—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a synbiotics with a bile acid metabolism improving function and application thereof. According to the invention, by matching the xylooligosaccharide and/or galactooligosaccharide with the bifidobacterium lactis MN-Gup, not only can the effect of reducing the body fat rate of the bifidobacterium lactis MN-Gup be achieved, but also the body fat rate can be reduced more remarkably; the synbiotics obtained by combining the bifidobacterium lactis MN-Gup with the xylo-oligosaccharide and/or the galacto-oligosaccharide also has the effect of balancing bile acid metabolism which is not possessed by the bifidobacterium lactis MN-Gup singly.

Description

Synbiotic with function of improving bile acid metabolism and application thereof
Technical Field
The invention relates to the field of microorganisms, in particular to a synbiotics with a bile acid metabolism improving function and application thereof.
Background
The prior art researches show that obesity can obviously increase the incidence rate of type II diabetes, hypertension, heart disease, various cancers, gout and cognitive dysfunction, increase the death risk of chronic disease patients and increasingly threaten human health.
The probiotic fermented milk is a well-known health food in the world, and has a clear effect of promoting intestinal health. Recent studies have shown that certain probiotic strains (e.g.bifidobacterium lactis MN-Gup) have an efficacy in preventing obesity. The known research results show that the probiotics and the products thereof have remarkable effects on improving indexes such as BMI, body fat rate, waistline, hip circumference and the like of obese people, and compared with saponin and alkaloid functional components, the probiotics have smaller influence on basic metabolism and higher safety.
However, the existing strain capable of preventing obesity has the action mechanism of preventing obesity mainly by regulating intestinal flora and organism inflammation balance so as to influence the organism glycolipid metabolic process, thereby improving the symptoms of fat accumulation and energy intake increase caused by obesity.
The latest researches find that the composition and the content of bile acid and secondary bile acid in intestinal tracts of obese people play an important role in the obesity process. For example: in the liver, hepatocytes metabolize cholesterol to bile acids that are secreted into the gut to aid in the digestion and absorption of lipid foods. In rats, most of cholic acid is conjugate of taurine, wherein the taurine, alpha and beta type of the rat bile acid is the bile acid with the largest content, and the secretion, synthesis and reabsorption of the bile acid to the liver are closely related to fatty liver, cholecystitis, diabetes, obesity and other diseases. Alleviation of obesity by balancing bile acid composition has become a potential target for obesity treatment. Therefore, it is necessary to provide a probiotic product for the market that is capable of balancing bile acid metabolism.
Disclosure of Invention
It is therefore an object of the present invention to provide a probiotic product which is capable of effectively balancing bile acid metabolism.
A synbiotics comprises bifidobacterium lactis MN-Gup and prebiotics, wherein the prebiotics are xylo-oligosaccharide and/or galacto-oligosaccharide.
Products comprising the synbiotics, wherein the added amount of the bifidobacterium lactis MN-Gup in the products is 1 multiplied by 10 8 -5×10 12 cfu/g, and the addition amount of the prebiotics in the product is 1-70wt%.
The product is a microbial agent, food or medicine; preferably yoghurt, liquid beverage, solid beverage, capsule, ice cream, pressed candy or meal replacement powder.
When the product is yogurt or liquid beverage, the addition amount of MN-Gup is 1×10 8 -5×10 8 cfu/g, the addition amount of prebiotics is 1.5-5wt%;
when the product is solid beverage or capsule, the addition amount of MN-Gup is 5×10 9 -5×10 12 cfu/g, the addition amount of the prebiotics is 10-70wt%.
When the prebiotics are xylo-oligosaccharide and galacto-oligosaccharide, the mass ratio of the xylo-oligosaccharide to the galacto-oligosaccharide is 1:1.
The product also comprises a strain with the function of improving the intestinal canal, wherein the strain with the function of improving the intestinal canal is at least one of bifidobacterium longum, bifidobacterium breve, bifidobacterium bifidum, bifidobacterium infantis, bifidobacterium animalis and lactobacillus paracasei;
the additive amount of the strain with the intestinal function improving function is not more than 50% of the additive amount of the bifidobacterium lactis MN-Gup.
The product of the invention also comprises whey protein powder;
the saccharide in the product is selected to be erythritol.
The use of the synbiotics of the invention in preparing products with the function of balancing bile acid metabolism; the product is the product containing synbiotics.
The product of the invention balances the bile acid metabolism function by improving the content of hyodeoxycholic acid and reducing the content of omega-rat bile acid.
Use of a synbiotics according to the present invention for the preparation of a product having any one of the following effects (a) - (c);
(a) The fat is reduced and the fat is reduced,
(b) The body fat rate is reduced, and the blood fat,
(c) Improving constipation;
the product is the product containing synbiotics.
The technical scheme of the invention has the following advantages:
1. the synbiotics provided by the invention consists of bifidobacterium lactis MN-Gup and prebiotics, wherein the prebiotics are xylo-oligosaccharide and/or galacto-oligosaccharide; according to the invention, by matching the xylooligosaccharide and/or galactooligosaccharide with the bifidobacterium lactis MN-Gup, not only can the effect of reducing the body fat rate of the bifidobacterium lactis MN-Gup be achieved, but also the body fat rate can be reduced more remarkably; the synbiotics obtained by combining the bifidobacterium lactis MN-Gup with the xylo-oligosaccharide and/or the galacto-oligosaccharide also has the effect of balancing bile acid metabolism which is not possessed by the bifidobacterium lactis MN-Gup singly.
2. In the product provided by the invention, the MN-Gup probiotics can be matched with other strains with the function of improving the intestinal canal, the strains with the function of improving the intestinal canal are at least one of bifidobacterium longum, bifidobacterium breve, bifidobacterium bifidum, bifidobacterium infantis, bifidobacterium animalis and lactobacillus paracasei, the additive amount of the strains with the function of improving the intestinal canal is not more than 1/2 of that of the MN-Gup, and the strains with the function of improving the intestinal canal can play a synergistic effect through the cooperation of multiple strains, for example: the MN-Gup is matched with the bifidobacterium lactis M8 for simultaneous use, so that constipation symptoms caused by high-fat diet can be relieved;
the product provided by the invention can also improve the nutrition attribute of the product by adding the whey protein powder, specifically, can promote the muscle synthesis of the organism by supplementing the whey protein powder, and can also provide a certain feeling of satiety and reduce appetite;
meanwhile, if sugar-containing products are involved, erythritol can be used for replacing sugar white granulated sugar, and the replacement can reduce energy intake, and 0.5g of erythritol can also provide cool and refreshing taste.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing the results of the adjustment of hyodeoxycholic acid content by synbiotics composed of different prebiotics and MN-Gup strain in example 1 of the present invention.
FIG. 2 is a graph showing the results of the regulation of omega-murine cholate content by synbiotics composed of different prebiotics and MN-Gup strains in example 1 of the present invention.
FIG. 3 is a graph showing the results of regulating body fat percentage of rats after yogurt is dried in example 2 of the present invention.
FIG. 4 is a graph showing the result of epididymal fat weight adjustment of rats after yogurt drying in example 2 of the present invention.
FIG. 5 is a graph showing the result of adjusting the weight of fat around the kidney of rats after the dry yogurt in example 2 of the present invention.
FIG. 6 is a graph showing the result of adjusting the content of hyodeoxycholic acid in rats after the dry yogurt in example 2 of the present invention.
FIG. 7 is a graph showing the result of adjusting the omega-cholate content of rats after the yogurt dry-off period in example 2 of the present invention.
FIG. 8 is a graph showing the result of adjusting the content of hyodeoxycholic acid in the solid beverage of example 3 of the present invention.
FIG. 9 is a graph showing the result of adjusting omega-mouse bile acid content of the solid beverage of example 3 according to the present invention.
FIG. 10 is a graph showing the result of adjusting the content of hyodeoxycholic acid in the capsule of example 4 of the present invention.
FIG. 11 is a graph showing the results of the regulation of omega-murine cholate content by the capsule of example 4 of the present invention.
Detailed Description
The following examples are provided for a better understanding of the present invention and are not limited to the preferred embodiments described herein, but are not intended to limit the scope of the invention, any product which is the same or similar to the present invention, whether in light of the present teachings or in combination with other prior art features, falls within the scope of the present invention.
The specific experimental procedures or conditions are not noted in the examples and may be followed by the operations or conditions of conventional experimental procedures described in the literature in this field. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
Example 1
A synbiotics capable of balancing bile acid metabolism comprises bifidobacterium lactis MN-Gup and prebiotics. The prebiotics refer to the combination of the probiotic strains and the prebiotics, and the prebiotics refer to the water-soluble oligosaccharides such as inulin, fructo-oligosaccharide, galacto-oligosaccharide, mannooligosaccharide, xylo-oligosaccharide and the like which can specifically promote the proliferation of the probiotics or promote the action and effect of the probiotics, and aiming at the bifidobacterium lactis MN-Gup in the invention, the prebiotics capable of promoting the proliferation of the probiotics include, but are not limited to, inulin, fructo-oligosaccharide, galacto-oligosaccharide, mannooligosaccharide, xylo-oligosaccharide and the like.
In the embodiment, the synbiotics composed of MN-Gup and the various probiotics are applied to the flora in the fresh feces of adult males with BMI more than or equal to 28, and the influence of the synbiotics on the levels of hyodeoxycholic acid and omega-murine cholic acid is verified, wherein the specific test process is as follows:
randomly selecting fresh feces of 3 adult males with BMI not less than 28, extracting bacterial colony, adding 50ml of MRS liquid culture medium, dividing into several groups, wherein one group is blank control group, and the other groups are respectively provided with 1×10 additives 10 cfu/mL of bifidobacterium lactis MN-Gup probiotics and prebiotics with the addition amount of 3 weight percent, wherein the prebiotics of each group are respectively inulin, galactooligosaccharide (GOS), xylooligosaccharide (XOS), mannooligosaccharide (MOS) and Fructooligosaccharide (FOS), and a group of independently added bifidobacterium lactis MN-Gup groups are used as a control group. Wherein, each group of culture medium is also added withAfter anaerobic incubation for 6 hours, 0.3wt% cholate (Solebao, cat# IC 1100) levels of hyodeoxycholic acid, omega-murine cholic acid in the medium were detected by conventional liquid chromatography-mass spectrometry methods.
The results of the above test are shown in FIG. 1 and Table 1.
TABLE 1
In two kinds of bile acid in the flora of obese people, the content of hyodeoxycholic acid is reduced compared with that of normal people, and the content of omega-rat bile acid is higher than that of normal people. As can be seen from the results of table 1 and fig. 1-2, respectively: the separate addition of MN-Gup strain has no obvious influence on the content of hyodeoxycholic acid and omega-rat bile acid; in the different prebiotic compound groups, the content of the hyodeoxycholic acid is obviously increased and the content of omega-rat bile acid is obviously reduced after the xylo-oligosaccharide and galacto-oligosaccharide groups are added. In the synbiotics formed by compounding the MN-Gup strain and other probiotics, the content of hyodeoxycholic acid and the content of omega-mousehole are not obviously influenced.
The above results indicate that: the synbiotics composed of the xylo-oligosaccharide or galacto-oligosaccharide and the MN-Gup strain can obviously achieve the purpose of regulating the bile acid level of the flora metabolism of obese people, and has obvious effect on the regulation of obesity.
Example 2
The embodiment provides a yogurt containing synbiotics, which comprises raw materials of 1kg of fresh raw milk, 0.05g-80g of sweetener, 0.01-0.05 g of fermentation strain, 0.1-0.5g of MN-Gup bacterial powder (each gram of bacterial powder contains MN-Gup1 multiplied by 10) 12 cfu), 15g-45g of prebiotics; wherein the prebiotics are xylo-oligosaccharide or/and galacto-oligosaccharide; when the sweetener is erythritol, the adding amount is 40g-80g; when the sweetener is sucralose, the addition amount is 0.05-0.2g; when the sweetener is sucrose, the addition amount is 60-80g; the specific proportion of the yoghourt is as follows:
raw material 1 of yoghurt, 1kg of fresh raw milk, 60g of erythritol, 0.03g of fermentation strain, 0.2g of MN-Gup bacterial powder (each gram of bacterial powder contains MN-Gup1 multiplied by 10) 12 cfu), oligomeric wood30g of sugar;
raw material of yoghurt 2 comprises fresh raw milk 1kg, sucralose 0.15g, ferment strain 0.03g, MN-Gup powder 0.5g (each gram of powder contains MN-Gup1×10) 12 cfu), 15g of prebiotics mixed by xylo-oligosaccharide and galacto-oligosaccharide according to a ratio of 1:1;
raw material of yoghurt 3 comprises fresh raw milk 1kg, erythritol 60g, ferment strain 0.03g, whey protein powder 40g, MN-Gup powder 0.2g (each gram of powder contains MN-Gup1×10) 12 cfu), 30g of galacto-oligosaccharide;
raw material of yoghurt 4 comprises fresh raw milk 1kg, sucrose 70g, ferment strain 0.03g, whey protein powder 50g, MN-Gup powder 0.1g (each gram of powder contains MN-Gup1×10) 12 cfu), 45g of prebiotics mixed by xylo-oligosaccharide and galacto-oligosaccharide according to a ratio of 1:1;
raw material 5 of yoghurt, 1kg of fresh raw milk, 70g of sucrose, 0.03g of fermentation strain, 0.3g of MN-Gup bacterial powder (each gram of bacterial powder contains MN-Gup1 multiplied by 10) 12 cfu), 30g of xylo-oligosaccharide.
The fermentation strains adopted in the embodiment are the combined fermentation agent of streptococcus thermophilus and lactobacillus bulgaricus, and the fermentation activity is 200-300U.
The preparation process of the yoghurt comprises the following steps:
1. standardization: regulating the protein content of fresh raw milk to 3.0-3.5 by adding deionized water;
2. preheating: setting the temperature in a water bath kettle to be 60-65 ℃, mixing other raw materials except the fermentation strain and the MN-Gup fungus powder according to the composition and the proportion of the raw materials of the yoghurt, and stirring until the raw materials are fully dissolved;
3. homogenizing: after the temperature of the sample is raised to 65 ℃, homogenizing, setting the primary pressure of a homogenizer to 40-80 and the secondary pressure of the homogenizer to 200-250, and homogenizing;
4. and (3) sterilization: heating in 95 ℃ water bath for 5 minutes to sterilize;
5. inoculating: cooling to 42 ℃ after sterilization, inoculating fermentation strain, adding bifidobacterium lactis MN-Gup bacterial powder, and uniformly mixing;
6. fermentation: fermenting in an incubator at 42 deg.C, and stopping fermentation when pH value is measured to be 4.6;
7. demulsification: stirring for 2 minutes by a stirrer 400r to carry out demulsification;
8. cooling: cooling to below 18+/-2 ℃ in a low-temperature water bath pot;
9. and (5) subpackaging: the samples were dispensed into sterile containers.
The yogurt prepared by the yogurt raw materials 1 and 3 is used for rat experiments, meanwhile, yogurt finished products without prebiotics added on the basis of the raw materials 1 and 3 are used as controls, and the specific experimental process is as follows:
after 5-week-old male SPF-grade SD rats are selected, 70 rats enter animal houses, are fed with maintenance feed (Vetong Lihua, SPF-grade rats and mice are commonly maintained with the feed) for 7 days to adapt to the environment, are randomly divided into 2 groups according to the weight range after the adaptation period is finished, one group is 12, the other group is 58, wherein the mice in 12 groups are fed with the maintenance feed as blank control groups, the rest mice are fed with high-fat feed (Vetong Lihua, SPF-grade rats and mice are high-fat feed), and the feeding amount, the sprinkling amount and the residual feeding amount are recorded every week, and the weight is weighed once and the feeding is carried out for 5-6 weeks. After 5-6 weeks, the groups fed with the high-fat feed are ordered according to weight gain, fat resistant mice with weight gain lower than 15% are eliminated, the rest mice are randomly divided into 4 groups, product intervention is carried out, the intervention is continued for 6 weeks, the intervention substances are administrated by gastric lavage every day, the gastric lavage dosage is 2 mL/time, and the gastric lavage is carried out every day for 1 time. Specific groupings of product interventions and the intervention composition are shown in table 2 below.
TABLE 2
In the product intervention process, the B-E group is continuously fed with the high-fat feed for 6 weeks; the blank group (group a) was perfused with normal saline while the maintenance feed was administered.
After the product intervention is finished, comparing the body fat rate, epididymal fat and perirenal fat weight, and detecting the content of hyodeoxycholic acid and omega-murine cholate in the feces, wherein the detection results are shown in figures 3-7.
As can be seen from fig. 3-5: the MN-Gup group body fat rate and epididymal fat and perirenal fat weight are obviously reduced, and the improvement effect of the synbiotics added with xylo-oligosaccharide or galacto-oligosaccharide is more obvious than that of the synbiotics added with MN-Gup probiotics. The results show that: the effect of reducing the body fat rate of MN-Gup after the xylo-oligosaccharide or galacto-oligosaccharide is compounded by 1.5 percent is obviously improved.
As can be seen from fig. 6 to fig. 7: bile acid secretion levels correlated with the degree of obesity, in the results of fig. 6-7, MN-Gup single strain did not significantly improve hyodeoxycholic acid and omega-murine cholic acid levels, whereas the average of the two synbiotic-added yogurts was significantly improved for this group of hyodeoxycholic acid and omega-murine cholic acid. Specifically, the secretion of hyodeoxycholic acid is obviously increased, and the secretion of omega-murine cholic acid is obviously reduced; wherein the xylo-oligosaccharide group can even recover to the level of the normal group. The result shows that after 1.5% of xylo-oligosaccharide or galacto-oligosaccharide is added, the imbalance of hyodeoxycholic acid and omega-murine cholic acid caused by obesity can be improved, the capacity of MN-Gup for balancing the bile acid level is obviously improved, and the level of the MN-Gup is more similar to that of a normal diet rat group.
Example 3
In this example, a solid beverage containing synbiotics is provided, the raw materials including: 0.05 to 0.2g of MN-Gup bacterial powder (each gram of bacterial powder contains MN-Gup1 multiplied by 10) 12 cfu), 0.7-1 g of xylo-oligosaccharide or/and galacto-oligosaccharide and 0.2-0.3g of fruit powder; also comprises 0.5 to 1g of maltodextrin and/or 0.1 to 0.5g of white kidney bean extract; the solid beverage comprises the following components in parts by weight:
formula 1: MN-Gup bacterial powder 0.1g, xylooligosaccharide 0.8g, maltodextrin 0.8g and fruit powder 0.3g;
formula 2: MN-Gup bacterial powder 0.05g, xylo-oligosaccharide 0.7g, galacto-oligosaccharide 0.7g and fruit powder 0.2g;
formula 3: MN-Gup bacterial powder 0.1g, galacto-oligosaccharide 0.8g, maltodextrin 0.8g and fruit powder 0.3g;
formula 4: MN-Gup bacterial powder 0.2g, galacto-oligosaccharide 1g, xylo-oligosaccharide 1g, fruit powder 0.3g, maltodextrin 1g and white kidney bean extract 0.5g.
In-vitro culture experiments are carried out by adopting the solid beverage prepared in the formula 1, compared with maltodextrin with the same weight, the solid beverage and the maltodextrin are added in the amounts of 3 weight percent, and the specific experimental process is as follows:
the faeces of obese people with BMI more than or equal to 28 are randomly taken, treated by the method in the embodiment 1 and then divided into three groups, wherein one group is a blank control, the other two groups are respectively added with the solid beverage of the formula 1 and the common maltodextrin for in vitro culture, after anaerobic culture for 6 hours, the influence of the solid beverage and the maltodextrin on the metabolism of bile acid by the flora of the obese people is compared, and the detection results are shown in figure 8 and figure 9.
As can be seen from fig. 8 and 9, the solid beverage of formula 1 significantly improves the level of hyodeoxycholic acid in the feces of obese people, significantly reduces the level of omega-mouse gall acid, and has no obvious change in the control group. The results show that the solid beverage of the formula 1 has the effect of regulating the levels of hyodeoxycholic acid and omega-murine cholic acid in the feces of obese people.
Example 4
In this embodiment, a capsule containing synbiotics is provided, and the raw materials include: 0.05 to 0.2g of MN-Gup bacterial powder (each gram of bacterial powder contains MN-Gup1 multiplied by 10) 12 cfu), 0.1-1 g of prebiotics, wherein the prebiotics are xylo-oligosaccharide or/and galacto-oligosaccharide; when the prebiotics are xylo-oligosaccharide, the addition amount is 0.1-0.5g; when the prebiotics are galactooligosaccharides, the addition amount is 0.5-1 g; when the prebiotics are xylo-oligosaccharide and galacto-oligosaccharide, the addition amounts are 0.1-0.5g respectively. The capsule also comprises 0.5-1 g of erythritol; the specific proportion of the capsule is as follows:
formula 1: 0.1g of MN-Gup bacterial powder and 0.3g of xylo-oligosaccharide;
formula 2: MN-Gup bacterial powder 0.05g, xylo-oligosaccharide 0.1g and galacto-oligosaccharide 0.5g;
formula 3: MN-Gup bacterial powder 0.2g, galacto-oligosaccharide 0.8g and erythritol 0.8g.
In-vitro culture experiments are carried out by adopting the synbiotic capsules prepared in the formula 1, compared with maltodextrin with the same weight, the addition amounts of the synbiotic capsules and the maltodextrin are 1 weight percent, and the specific experimental process is as follows:
faeces of obese people with BMI more than or equal to 28 are treated according to the method in the embodiment 1 and then divided into three groups, wherein one group is blank control, the other two groups are respectively added with synbiotics capsules of the formula 1 and common maltodextrin for in vitro culture, after anaerobic culture for 6 hours, the formula 1 capsules are adopted to be compared with the equal weight maltodextrin capsules, the influence of the formula 1 capsules on the metabolism of bile acid of the obese people is compared, and the detection results are shown in fig. 10 and 11.
As can be seen from fig. 8 and 9, the capsule of formula 1 significantly improves the level of hyodeoxycholic acid in the feces of obese people, significantly reduces the level of omega-mouse gall acid, and has no obvious change in the blank group. The result shows that the capsule of the formula 1 has the effect of regulating the levels of hyodeoxycholic acid and omega-murine cholic acid in the feces of obese people.
Example 5
In this embodiment, a solid beverage containing a compound probiotic synbiotic is provided, and the raw materials include: 0.05 to 0.2g of MN-Gup bacterial powder (each gram of bacterial powder contains MN-Gup1 multiplied by 10) 12 cfu), probio-M8 bacterial powder 0.025-0.1 g (each gram of bacterial powder contains M8 1 multiplied by 10) 12 cfu), 0.7-1 g of xylo-oligosaccharide or/and galacto-oligosaccharide and 0.2-0.3g of fruit powder; also comprises 0.5 to 1g of maltodextrin and/or 0.1 to 0.5g of white kidney bean extract; the solid beverage comprises the following components in parts by weight:
formula 1: MN-Gup bacterial powder 0.1g, probio-M8 bacterial powder 0.05g, xylo-oligosaccharide 0.8g, maltodextrin 0.75g and fruit powder 0.3g;
formula 2: 0.1g of MN-Gup bacterial powder, 0.05g of Probio-M8 bacterial powder, 0.7g of xylo-oligosaccharide, 0.7g of galacto-oligosaccharide and 0.2g of fruit powder;
formula 3: MN-Gup bacterial powder 0.1g, probio-M8 bacterial powder 0.05g, galacto-oligosaccharide 0.8g, maltodextrin 0.75g and fruit powder 0.3g;
formula 4: MN-Gup bacterial powder 0.2g, probio-M8 bacterial powder 0.1g, galacto-oligosaccharide 1g, xylo-oligosaccharide 1g, fruit powder 0.3g, maltodextrin 1g and white kidney bean extract 0.5g.
The microorganism preservation number of the Probio-M8 is CGMCC No.18610; the preservation number of the MN-Gup is CGMCC No.15578.
The clinical experiment for improving constipation of obese people by adopting the synbiotic solid beverage prepared in the formula 1 is compared with the formula 1 in the embodiment 3, and meanwhile, an equal weight maltodextrin group is used as a control group, and the specific experimental process is as follows:
the 30 obese people with BMI of more than or equal to 28 and the number of times of defecation per week of less than or equal to 2 were recruited and randomly grouped into 3 groups, and the specific groups are shown in Table 3, and 2 solid beverages, 2 g/bar, were ingested daily. The subjects were counted for a weekly faeces discharge by taking for 28 days continuously.
TABLE 3 Table 3
The statistical results are shown in table 4 below.
TABLE 4 Table 4
As shown in the table 4, the defecation times of the MN-Gup combined tuple are obviously improved compared with those of the control group, and the M8 combined tuple is obviously improved compared with the MN-Gup combined tuple. The result shows that after the Mn-Gup synbiotics are compounded with M8, the constipation improvement effect of the MN-Gup synbiotics on obese people can be remarkably improved.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.

Claims (10)

1. The synbiotics is characterized by comprising bifidobacterium lactis MN-Gup and prebiotics, wherein the prebiotics are xylo-oligosaccharide and/or galacto-oligosaccharide.
2. Product comprising a synbiotics as claimed in claim 1, characterized in that the added amount of bifidobacterium lactis MN-Gup in the product is 1 x 10 8 -5×10 12 cfu/g, and the addition amount of the prebiotics in the product is 1-70wt%.
3. The product according to claim 2, wherein the product is a microbial agent, a food or a pharmaceutical product; preferably yoghurt, liquid beverage, solid beverage, capsule, ice cream, pressed candy or meal replacement powder.
4. The product according to claim 3, wherein,
when the product is yogurt or liquid beverage, the addition amount of MN-Gup is 1×10 8 -5×10 8 cfu/g, the addition amount of prebiotics is 1.5-5wt%;
when the product is solid beverage or capsule, the addition amount of MN-Gup is 5×10 9 -5×10 12 cfu/g, the addition amount of the prebiotics is 10-70wt%.
5. The product according to any one of claims 2 to 4, further comprising a strain having an improved intestinal function, wherein the strain having an improved intestinal function is at least one of bifidobacterium longum, bifidobacterium breve, bifidobacterium bifidum, bifidobacterium infantis, bifidobacterium animalis and lactobacillus paracasei.
6. The product according to claim 5, wherein the additive amount of the strain having the intestinal function is not more than 50% of the additive amount of bifidobacterium lactis MN-Gup.
7. The product of any one of claims 2-6, further comprising whey protein powder;
the saccharide in the product is selected to be erythritol.
8. Use of a synbiotics according to claim 1 for the preparation of a product having a function of balancing bile acid metabolism; the product is a product according to any one of claims 2-7.
9. Use according to claim 8, characterized in that bile acid metabolism is balanced by increasing the hyodeoxycholic acid content and decreasing the omega-murine cholate content.
10. Use of a synbiotics according to claim 1 for the preparation of a product having any one of the following effects (a) - (c);
(a) The fat is reduced and the fat is reduced,
(b) The body fat rate is reduced, and the blood fat,
(c) Improving constipation;
the product is a product according to any one of claims 2-7.
CN202210771360.6A 2022-06-30 2022-06-30 Synbiotic with function of improving bile acid metabolism and application thereof Pending CN117356711A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210771360.6A CN117356711A (en) 2022-06-30 2022-06-30 Synbiotic with function of improving bile acid metabolism and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210771360.6A CN117356711A (en) 2022-06-30 2022-06-30 Synbiotic with function of improving bile acid metabolism and application thereof

Publications (1)

Publication Number Publication Date
CN117356711A true CN117356711A (en) 2024-01-09

Family

ID=89389814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210771360.6A Pending CN117356711A (en) 2022-06-30 2022-06-30 Synbiotic with function of improving bile acid metabolism and application thereof

Country Status (1)

Country Link
CN (1) CN117356711A (en)

Similar Documents

Publication Publication Date Title
US11566219B2 (en) Bifidobacterium bacteria and composition including novel bifidobacterium bacteria
Hitchins et al. Prophylactic and therapeutic aspects of fermented milk
EP2604689B1 (en) Anti-obesity agent and anti-obesity food
CN109430666A (en) A kind of Freeze-dry Powder of Probioctics solid beverage
EP2127660B1 (en) Agent for reducing visceral fat
EP2552464A1 (en) Use of bifidobacteria for preventing allergy in breastfed infants
WO2019189200A1 (en) Nutritional composition, food/drink composition using nutritional composition, and modified milk powder using nutritional composition
JP7240327B2 (en) Novel bifidobacterium bacterium and composition containing the bacterium
TW201542216A (en) Novel lactobacillus paracasei strain
CN112155056A (en) Yoghourt for adjusting intestinal tract and preparation method and application thereof
KR101545551B1 (en) The composition containing combination of 7 probiotics which have efficacy preventing from insulin resistance which cause type 2 diabetes mellitus as a effector component
CN113755370A (en) Application of lactobacillus acidophilus LA85 in preparation of blood fat reducing medicines or health-care foods
WO2007013547A1 (en) Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food
CN117356711A (en) Synbiotic with function of improving bile acid metabolism and application thereof
JP7368484B2 (en) Composition, food and beverage compositions containing the composition, and formula milk
JP7152472B2 (en) Composition for promoting FGF21 secretion
EP4095232A1 (en) Bacterium, composition and method for producing same, and prebiotics composition
CN110839693A (en) Application of parabacteroides gibsonii in preventing or treating obesity or related diseases
CN111954536A (en) Composition for infants and young children for preventing diseases caused by hyperglycemia in school age and later
WO2024024906A1 (en) Composition for promoting utilization of oligosaccharide in bifidobacterium breve
JP7309436B2 (en) A composition for preventing or improving renal dysfunction, and pharmaceutical compositions and food and drink compositions using the composition for preventing or improving renal dysfunction
RU2771744C2 (en) Symbiotic composition for prevention of metabolic disorders
RU2771716C2 (en) Synbiotic composition for prevention of metabolic disorders
WO2023150628A2 (en) Probiotic strain selected by targeted in vivo enrichment to aid with healthy lactose digestion
CN115702655A (en) Middle-aged and old modified goat milk powder assisting in reducing blood fat and blood pressure and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination